I am a
Home I AM A Search Login

Papers of the Week


Papers: 9 Apr 2022 - 15 Apr 2022


Human Studies


2022 Apr 11


J Headache Pain


23


1

Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study.

Authors

Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
J Headache Pain. 2022 Apr 11; 23(1):47.
PMID: 35410121.

Abstract

The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, have been demonstrated in randomized, double-blind, placebo-controlled trials. Real-world data can further support those clinical trial data and demonstrate the full clinical benefits of fremanezumab. This chart review assessed the effectiveness of fremanezumab for improving clinical outcomes in adult patients with migraine treated according to real-world clinical practice.